Drugs / MVA-BN®-HER2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01152398 | Jun 2010 → Sep 2012 | breast cancer | Bavarian Nordic | Completed | No outcome recorded |
| Phase 1 | NCT00485277 | Jun 2007 → Sep 2010 | breast cancer | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-HER2 | “MVA-BN®-HER2 is a candidate breast cancer immunotherapy product comprised of a highly attenuated non-replicating vaccinia virus, MVA-BN®, engineered to encode a modified form...” NCT01152398 ↗2“MVA-BN®-HER2 is a candidate breast cancer immunotherapy product comprised of a highly attenuated non-replicating vaccinia virus, MVA-BN®, engineered to encode a modified form...” NCT00485277 ↗ |
| Modality | Vaccine | “Experimental vaccine, subcutaneous injection q3weeks x 3” NCT00485277 ↗ |
| Route | Subcutaneous | “Patients will receive 3 subcutaneous vaccinations at 3 week intervals” NCT00485277 ↗ |